Bank of America’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-34,480
| Closed | -$76.2K | – | 8067 |
|
|
2023
Q2 | $76.2K | Sell |
34,480
-24,438
| -41% | -$50.7K | ﹤0.01% | 6306 |
|
|
2023
Q1 | $150K | Sell |
58,918
-19,279
| -25% | -$38.1K | ﹤0.01% | 6064 |
|
|
2022
Q4 | $146K | Buy |
78,197
+16,191
| +26% | +$40.4K | ﹤0.01% | 6081 |
|
|
2022
Q3 | $159K | Sell |
62,006
-4,775
| -7% | -$11.9K | ﹤0.01% | 6115 |
|
|
2022
Q2 | $129K | Sell |
66,781
-76,588
| -53% | -$167K | ﹤0.01% | 6346 |
|
|
2022
Q1 | $426K | Buy |
143,369
+27,249
| +23% | +$103K | ﹤0.01% | 5941 |
|
|
2021
Q4 | $522K | Sell |
116,120
-38,604
| -25% | -$183K | ﹤0.01% | 5824 |
|
|
2021
Q3 | $751K | Buy |
154,724
+9,449
| +7% | +$52.1K | ﹤0.01% | 5321 |
|
|
2021
Q2 | $991K | Sell |
145,275
-27,672
| -16% | -$224K | ﹤0.01% | 4916 |
|
|
2021
Q1 | $1.22M | Buy |
172,947
+29,620
| +21% | +$213K | ﹤0.01% | 4668 |
|
|
2020
Q4 | $897K | Sell |
143,327
-74,894
| -34% | -$441K | ﹤0.01% | 4598 |
|
|
2020
Q3 | $1.18M | Buy |
218,221
+34,186
| +19% | +$169K | ﹤0.01% | 4086 |
|
|
2020
Q2 | $961K | Buy |
184,035
+160,848
| +694% | +$714K | ﹤0.01% | 4138 |
|
|
2020
Q1 | $73K | Sell |
23,187
-4,158
| -15% | -$15.3K | ﹤0.01% | 5698 |
|
|
2019
Q4 | $110K | Sell |
27,345
-3,769
| -12% | -$13.1K | ﹤0.01% | 5957 |
|
|
2019
Q3 | $135K | Buy |
31,114
+4,949
| +19% | +$19.8K | ﹤0.01% | 5898 |
|
|
2019
Q2 | $105K | Sell |
26,165
-3,153
| -11% | -$15K | ﹤0.01% | 5988 |
|
|
2019
Q1 | $157K | Buy |
29,318
+5,814
| +25% | +$37.5K | ﹤0.01% | 5644 |
|
|
2018
Q4 | $120K | Buy |
23,504
+7,074
| +43% | +$53.7K | ﹤0.01% | 5814 |
|
|
2018
Q3 | $160K | Sell |
16,430
-2,667
| -14% | -$26.9K | ﹤0.01% | 5612 |
|
|
2018
Q2 | $194K | Sell |
19,097
-1,131
| -6% | -$12.8K | ﹤0.01% | 5432 |
|
|
2018
Q1 | $263K | Buy |
20,228
+12,560
| +164% | +$187K | ﹤0.01% | 5214 |
|
|
2017
Q4 | $137K | Sell |
7,668
-5,759
| -43% | -$120K | ﹤0.01% | 5597 |
|
|
2017
Q3 | $337K | Buy |
13,427
+3,259
| +32% | +$75.9K | ﹤0.01% | 5160 |
|
|
2017
Q2 | $246K | Sell |
10,168
-925
| -8% | -$20.4K | ﹤0.01% | 5227 |
|
|
2017
Q1 | $214K | Buy |
11,093
+2,407
| +28% | +$37.9K | ﹤0.01% | 5281 |
|
|
2016
Q4 | $133K | Buy |
8,686
+5,774
| +198% | +$75K | ﹤0.01% | 5500 |
|
|
2016
Q3 | $38K | Sell |
2,912
-5,410
| -65% | -$71.7K | ﹤0.01% | 5842 |
|
|
2016
Q2 | $116K | Buy |
8,322
+6,322
| +316% | +$93.1K | ﹤0.01% | 5447 |
|
|
2016
Q1 | $30K | Sell |
2,000
-295
| -13% | -$4.51K | ﹤0.01% | 5979 |
|
|
2015
Q4 | $44K | Sell |
2,295
-992
| -30% | -$18.9K | ﹤0.01% | 6098 |
|
|
2015
Q3 | $62K | Buy |
3,287
+1,729
| +111% | +$43.1K | ﹤0.01% | 5871 |
|
|
2015
Q2 | $40K | Sell |
1,558
-4,062
| -72% | -$115K | ﹤0.01% | 6047 |
|
|
2015
Q1 | $176K | Buy |
5,620
+4,290
| +323% | +$123K | ﹤0.01% | 5008 |
|
|
2014
Q4 | $51K | Buy |
1,330
+213
| +19% | +$5.09K | ﹤0.01% | 6334 |
|
|
2014
Q3 | $27K | Sell |
1,117
-4,118
| -79% | -$108K | ﹤0.01% | 6886 |
|
|
2014
Q2 | $125K | Sell |
5,235
-11
| -0.2% | -$359 | ﹤0.01% | 5949 |
|
|
2014
Q1 | $194K | Buy |
5,246
+29
| +0.6% | +$1.15K | ﹤0.01% | 5463 |
|
|
2013
Q4 | $210K | Hold |
5,217
| – | – | ﹤0.01% | 5555 |
|
|
2013
Q3 | $199K | Sell |
5,217
-2,269
| -30% | -$81.2K | ﹤0.01% | 5453 |
|
|
2013
Q2 | $271K | Buy |
+7,486
| New | +$321K | ﹤0.01% | 5330 |
|
Bank of America's PRTK Position: Q3 2023 in Review
Bank of America sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 34,480 shares — an estimated $76.2K sold.
Bank of America first reported a position in PRTK in Q2 2013 and held it in 41 quarters. The position peaked at $1.22M in Q1 2021. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Bank of America reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Bank of America sold 34,480 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $76.2K.
- Bank of America first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 41 quarters.
- Bank of America's Paratek Pharmaceuticals, Inc. position peaked at $1.22M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Bank of America's 13F filing for Q3 2023, filed 14 Nov 2023.